Stock listing
NASDAQ:MBOT Microbot Medical Inc. Stock
Home listing (NASDAQ) of Microbot Medical Inc.
Follow Microbot Medical Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:MBOT
$0.68 USD -0.04 (-5.7%)
Close on Nov 20, 2026
- Day range
- $0.66 – $0.75 USDNov 20, 2026
- Volume
- 1.72M sharesNov 20, 2026
- Market cap
- $45.67M USDAt the close on Nov 20, 2026 · price × 67.16M shares outstanding
- 52-week range
- $0.522 – $2.86 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $952,589 USDMedian day 587,559 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MBOT · Home | $0.68 USD | -0.041 (-5.7%) | 1,722,216 | $0.73 | $0.75 | $0.66 | $0.721 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MBOT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.68 | -0.041 | -5.7% | $0.73 | $0.75 | $0.66 | 1,722,216 | |
| $0.721 | +0.032 | +4.7% | $0.689 | $0.73 | $0.675 | 1,296,549 | |
| $0.689 | +0.045 | +6.9% | $0.672 | $0.72 | $0.631 | 1,709,217 | |
| $0.644 | -0.334 | -34.2% | $0.65 | $0.664 | $0.522 | 10,182,780 | |
| $0.979 | -0.051 | -5.0% | $1.04 | $1.05 | $0.95 | 1,163,780 | |
| $1.03 | -0.08 | -7.2% | $1.10 | $1.10 | $1.03 | 950,151 | |
| $1.11 | +0.06 | +5.7% | $1.07 | $1.12 | $1.07 | 881,154 | |
| $1.05 | -0.05 | -4.5% | $1.10 | $1.11 | $1.03 | 1,065,306 | |
| $1.10 | -0.01 | -0.9% | $1.11 | $1.15 | $1.09 | 733,296 | |
| $1.11 | +0.04 | +3.7% | $1.10 | $1.12 | $1.05 | 817,268 | |
| $1.07 | -0.07 | -6.1% | $1.15 | $1.16 | $1.03 | 1,456,967 | |
| $1.14 | +0.05 | +4.6% | $1.10 | $1.15 | $1.10 | 782,480 | |
| $1.09 | +0.05 | +4.8% | $1.05 | $1.09 | $1.025 | 1,210,908 | |
| $1.04 | -0.05 | -4.6% | $1.10 | $1.18 | $1.03 | 1,082,058 | |
| $1.09 | -0.03 | -2.7% | $1.11 | $1.11 | $1.04 | 1,334,951 | |
| $1.12 | 0.00 | 0.0% | $1.09 | $1.125 | $1.05 | 968,346 | |
| $1.12 | +0.09 | +8.7% | $1.11 | $1.15 | $1.061 | 1,882,401 | |
| $1.03 | +0.088 | +9.4% | $0.964 | $1.066 | $0.964 | 1,156,154 | |
| $0.942 | -0.032 | -3.3% | $0.981 | $1.00 | $0.941 | 485,326 | |
| $0.974 | +0.032 | +3.4% | $0.963 | $0.993 | $0.963 | 569,354 | |
| $0.942 | +0.002 | +0.2% | $0.93 | $0.959 | $0.93 | 298,058 | |
| $0.94 | -0.007 | -0.8% | $0.98 | $0.98 | $0.94 | 485,259 | |
| $0.948 | -0.005 | -0.6% | $0.958 | $1.03 | $0.945 | 725,289 | |
| $0.953 | +0.003 | +0.3% | $0.95 | $0.973 | $0.944 | 389,479 | |
| $0.95 | 0.00 | 0.0% | $0.955 | $1.00 | $0.945 | 803,001 | |
| $0.95 | -0.042 | -4.2% | $0.98 | $0.99 | $0.93 | 1,413,635 | |
| $0.992 | -0.028 | -2.8% | $1.01 | $1.03 | $0.99 | 568,186 | |
| $1.02 | -0.02 | -1.9% | $1.03 | $1.039 | $1.005 | 384,973 | |
| $1.04 | -0.03 | -2.8% | $1.07 | $1.08 | $1.03 | 423,584 | |
| $1.07 | 0.00 | 0.0% | $1.08 | $1.085 | $1.05 | 637,699 | |
| $1.07 | -0.05 | -4.5% | $1.12 | $1.15 | $1.06 | 564,616 | |
| $1.12 | +0.05 | +4.7% | $1.08 | $1.16 | $1.07 | 649,759 | |
| $1.07 | 0.00 | 0.0% | $1.09 | $1.165 | $1.05 | 1,993,348 | |
| $1.07 | -0.09 | -7.8% | $1.15 | $1.16 | $1.05 | 1,910,284 | |
| $1.16 | -0.04 | -3.3% | $1.23 | $1.23 | $1.14 | 852,404 | |
| $1.20 | 0.00 | 0.0% | $1.21 | $1.23 | $1.18 | 685,514 | |
| $1.20 | -0.045 | -3.6% | $1.25 | $1.26 | $1.20 | 518,813 | |
| $1.245 | -0.005 | -0.4% | $1.27 | $1.28 | $1.22 | 631,353 | |
| $1.25 | -0.025 | -2.0% | $1.27 | $1.28 | $1.24 | 424,654 | |
| $1.275 | -0.035 | -2.7% | $1.32 | $1.33 | $1.26 | 485,330 | |
| $1.31 | 0.00 | 0.0% | $1.30 | $1.32 | $1.29 | 310,503 | |
| $1.31 | -0.07 | -5.1% | $1.39 | $1.39 | $1.31 | 461,006 | |
| $1.38 | +0.03 | +2.2% | $1.35 | $1.39 | $1.28 | 1,331,794 | |
| $1.35 | -0.01 | -0.7% | $1.36 | $1.39 | $1.34 | 572,436 | |
| $1.36 | -0.06 | -4.2% | $1.42 | $1.43 | $1.35 | 694,905 | |
| $1.42 | -0.02 | -1.4% | $1.45 | $1.47 | $1.42 | 388,464 | |
| $1.44 | 0.00 | 0.0% | $1.44 | $1.48 | $1.43 | 289,588 | |
| $1.44 | -0.01 | -0.7% | $1.45 | $1.47 | $1.43 | 345,779 | |
| $1.45 | 0.00 | 0.0% | $1.43 | $1.495 | $1.42 | 406,121 | |
| $1.45 | -0.01 | -0.7% | $1.49 | $1.49 | $1.44 | 446,978 | |
| $1.46 | 0.00 | 0.0% | $1.45 | $1.475 | $1.45 | 203,023 | |
| $1.46 | -0.04 | -2.7% | $1.49 | $1.50 | $1.45 | 293,567 | |
| $1.50 | +0.06 | +4.2% | $1.46 | $1.515 | $1.45 | 560,220 | |
| $1.44 | 0.00 | 0.0% | $1.48 | $1.48 | $1.44 | 406,883 | |
| $1.44 | -0.02 | -1.4% | $1.48 | $1.489 | $1.44 | 385,827 | |
| $1.46 | -0.01 | -0.7% | $1.46 | $1.52 | $1.46 | 539,798 | |
| $1.47 | -0.02 | -1.3% | $1.49 | $1.50 | $1.465 | 328,317 | |
| $1.49 | +0.01 | +0.7% | $1.49 | $1.50 | $1.46 | 404,904 | |
| $1.48 | -0.02 | -1.3% | $1.50 | $1.51 | $1.46 | 467,739 | |
| $1.50 | -0.02 | -1.3% | $1.51 | $1.54 | $1.49 | 400,396 | |
| $1.52 | +0.02 | +1.3% | $1.53 | $1.53 | $1.47 | 563,548 | |
| $1.50 | +0.02 | +1.4% | $1.49 | $1.53 | $1.475 | 587,559 | |
| $1.48 | -0.02 | -1.3% | $1.50 | $1.57 | $1.47 | 1,515,036 | |
| $1.50 | +0.01 | +0.7% | $1.50 | $1.53 | $1.49 | 334,149 | |
| $1.49 | -0.06 | -3.9% | $1.56 | $1.566 | $1.48 | 613,676 |
Splits
4 splits since 2011 · NASDAQ:MBOT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation | |
| 1-for-9 | Consolidation | |
| 1-for-12 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:MBOT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Microbot Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements
Latest deck · Mar 17, 2026
Investor Presentation (March 2026)
Investor deck · 35 slides
Latest news
Microbot Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements
Nov 16, 2026
Closed $0.644 (-34.2%) on Nov 16, 2026
Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion
Nov 5, 2026
Closed $1.07 (-6.1%) on Nov 5, 2026
Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic System
Oct 27, 2026
Closed $1.03 (+9.4%) on Oct 27, 2026
Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.
Oct 23, 2026
Closed $0.974 (+3.4%) on Oct 23, 2026
Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio
Oct 20, 2026
Closed $0.948 (-0.6%) on Oct 20, 2026
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Oct 6, 2026
Closed $1.07 (0.0%) on Oct 6, 2026
Microbot Medical® Highlights Growth Strategy
Sep 25, 2026
Closed $1.25 (-2.0%) on Sep 28, 2026
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Aug 11, 2026
Closed $1.68 (-13.2%) on Aug 11, 2026
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
Jul 21, 2026
Closed $1.80 (+0.6%) on Jul 21, 2026
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
Jul 7, 2026
Closed $1.90 (-1.6%) on Jul 7, 2026
Microbot Medical Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 38 in the last 12 months · 172 in all · newest Nov 16, 2026 · oldest 2019
- Decks
- 19 decks · latest Mar 17, 2026
Where Microbot Medical Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MBOT · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A2N5AS | LS Exchange | Germany | EUR |
| BOATS:MBOT | BOATS | United States | USD |
| Frankfurt:CY9D | Frankfurt | Germany | EUR |
| gettex:CY9D | gettex | Germany | EUR |
| Lang & Schwarz:A2N5AS | Lang & Schwarz | Germany | EUR |
| Tradegate:CY9D | Tradegate | Germany | EUR |
| Dusseldorf:CY9D | Dusseldorf | Germany | EUR |
| Hamburg:CY9D | Hamburg | Germany | EUR |
| Munich:CY9D | Munich | Germany | EUR |
| Stuttgart:CY9D | Stuttgart | Germany | EUR |
Valuation
EV/sales −38.6× against a median of 2.9×: the lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$16.16M USD
- P/E
- Loss
- EV/sales
- −38.6×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.7×
- Gross margin
- −400.5%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.82
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Microbot Medical Inc. · NASDAQ:MBOT | US$45.67M | −US$16.16M | n/a | −38.6× | n/a | 0.7× | n/a | 0.0× | 1.82 |
| Venus Medtech (Hangzhou), Inc. Class H · HKEX:2500 | US$48.32M | US$65.50M | n/a | 1.4× | n/a | 0.2× | −132.9% | 0.1× | n/a |
| Medimaging Integrated Solution Inc. · TWSE:6796 | US$48.03M | US$43.05M | 111× | 2.1× | 28.6× | 1.9× | 2.1% | 0.5× | n/a |
| Conexeu Sciences Inc. · NASDAQ:CNXU | US$47.79M | US$45.82M | n/a | n/a | n/a | 8.2× | n/a | 0.0× | 2.08 |
| RenovoRx, Inc. · NASDAQ:RNXT | US$45.45M | US$35.27M | n/a | 12.7× | n/a | 4.9× | −469.0% | 0.0× | 1.71 |
| Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. · BIST:ONCSM | US$45.25M | US$45.28M | 31.7× | 2.9× | 7.5× | 4.5× | 9.0% | 0.1× | n/a |
| Bactiguard Holding AB · OMXSTO:BACTI_B | US$45.14M | US$54.81M | 76.6× | 2.6× | 12.5× | 1.5× | 2.8% | 0.5× | n/a |
| Somnomed Limited · ASX:SOM | US$45.09M | US$37.33M | n/a | 0.5× | 8.7× | 1.4× | −2.3% | 0.1× | n/a |
| Nuo Therapeutics Inc · OTC:AURX | US$44.38M | US$44.30M | n/a | 7.3× | n/a | n/a | −31.5% | n/a | 0.73 |
| Ortoma AB Class B · OMXSTO:ORT_B | US$44.27M | US$38.13M | n/a | 11.7× | n/a | 2.6× | −197.7% | 0.0× | n/a |
| BrainCool AB · OMXSTO:BRAIN | US$43.31M | US$39.09M | n/a | 9.8× | n/a | 2.8× | −84.7% | 0.0× | n/a |
| Median of the others | US$45.20M | US$43.67M | 76.6× | 2.9× | 10.6× | 2.6× | −31.5% | 0.1× | 1.71 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.32 · 3 analysts
- Revenue, year to Dec 2026
- 700K · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Harel Gadot | CEO, President and Chairman |
| Rachel Vaknin | Chief Financial Officer |
| Allison Rosefort | VP, Marketing |
| Alon Tamir | VP, Sales, EMEA |
| Christina Bailey | VP, Sales |
| Earl Adamy | VP, Strategic Marketing & Business Development |
| Eran Cohen | VP, Global Integration |
| Naama Moav | VP, Human Resources |
| Noa Ofer | VP, Quality Assurance and Regulatory Affairs |
| Juan Diaz-Cartelle | Chief Medical Officer |
| Simon Sharon | GM, Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Harel Gadot | CEO, President and Chairman |
| Aileen Stockburger | Director |
| David Wilson | Director |
| Martin J. Madden | Director |
| Scott Burell | Director |
| Tal Wenderow | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −34.2% |
| Q2 2026 | Aug 11, 2026 · Before open | −13.2% |
| Q1 2026 | May 12, 2026 | −0.9% |
| Q4 2025 | Mar 26, 2026 · After close | −8.8% |
| Q3 2025 | Nov 12, 2025 · After close | −6.1% |
| Q2 2025 | Aug 12, 2025 · After close | −2.6% |
| Q1 2025 | May 14, 2025 · After close | +8.5% |
| Q4 2024 | Mar 25, 2025 · After close | −4.4% |
| Q3 2024 | Nov 13, 2024 · After close | −5.0% |
| Q2 2024 | Aug 14, 2024 · After close | +1.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · Before open | −2.1% |
| Q4 2023 | Mar 27, 2024 · After close | +7.0% |
| Q3 2023 | Nov 14, 2023 · After close | +2.2% |
| Q2 2023 | Aug 14, 2023 · Before open | −0.5% |
| Q1 2023 | May 17, 2023 · After close | −4.2% |
| Q4 2022 | Mar 31, 2023 · After close | 0.0% |
| Q3 2022 | Nov 14, 2022 · After close | +11.8% |
| Q2 2022 | Aug 15, 2022 · After close | −2.3% |
| Q1 2022 | May 16, 2022 · After close | +4.2% |
| Q4 2021 | Mar 31, 2022 · After close | +0.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2026) | Investor deck | 35 slides | Mar 17, 2026 |
| Investor Presentation (September 2025) | Investor deck | 21 slides | Sep 9, 2025 |
| Investor Presentation (April 2025) | Investor deck | 20 slides | Apr 30, 2025 |
| Investor Presentation (October 2024) | Investor deck | 19 slides | Oct 31, 2024 |
| Investor Presentation (September 2024) | Investor deck | 25 slides | Sep 11, 2024 |
| Investor Presentation (April 2024) | Investor deck | 15 slides | Apr 24, 2024 |
| Investor Presentation (April 2022) | Investor deck | 11 slides | Apr 12, 2022 |
| Investor Presentation (January 2022) | Investor deck | 11 slides | Jan 10, 2022 |
| Investor Presentation (September 2021) | Investor deck | 24 slides | September 2021 |
| Investor Presentation (March 2021) | Investor deck | 26 slides | March 2021 |
All 19 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2021) | Investor deck | 23 slides | Jan 14, 2021 |
| Investor Presentation (August 2020) | Investor deck | 21 slides | Aug 17, 2020 |
| Investor Presentation (January 2020) | Investor deck | 17 slides | Jan 13, 2020 |
| Investor Presentation (October 2018) | Investor deck | 24 slides | Oct 1, 2018 |
| Investor Presentation (September 2018) | Investor deck | 23 slides | Sep 4, 2018 |
| Ladenburg Thalmann 2017 Healthcare Conference | Conference | 33 slides | Sep 26, 2017 |
| Conference Presentation (September 2017) | Conference | 33 slides | Sep 8, 2017 |
| Micro Cap Conference 2017 | Conference | 31 slides | April 2017 |
| Roth Conference (December 2016) | Conference | 31 slides | December 2016 |
Financings
| Raise | Date |
|---|---|
| Warrant exercise of common shares on exercise of outstanding preferred investment options Closed: US$2.8M in the latest tranche · US$2.1 a share · Warrants at US$4.5 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Development, commercialization and regulatory work for the LIBERTY Robotic System, potential acquisitions, new applications, working capital | Oct 7, 2025 |
| Registered direct offering of common stock with concurrent private placement of short-term series I preferred investment options Closed: US$13M raised · US$2.13 a share · Warrants at US$2.13 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Development, commercialization and regulatory work for the LIBERTY Robotic System, new applications from its IP, working capital and general corporate purposes | Feb 11, 2025 |
| Registered direct offering of common stock with concurrent private placement of short-term series H preferred investment options Closed: US$8.6M raised · US$2.27 a share · Warrants at US$2.1 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Development, commercialization and regulatory activities for the LIBERTY Robotic System, new applications from its IP, working capital and general purposes | Jan 10, 2025 |
| Registered direct offering of common stock with concurrent private placement of short-term series G preferred investment options Closed: US$7M raised · US$1.75 a share · Warrants at US$1.75 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Development, commercialization and regulatory activities for the LIBERTY Robotic System, new applications from its IP, working capital and general corporate purposes | Jan 7, 2025 |
| At-the-market programme of common stock Tranche closed: US$4.8M raised | Jan 7, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 47.0K | 91.0K | 106.0K | 102.0K | 76.0K | 68.0K | 84.0K | 54.0K | 21.0K | 10.0K |
| Gross profit | -47.0K | -91.0K | -106.0K | -102.0K | -76.0K | -68.0K | -84.0K | -54.0K | -21.0K | -10.0K |
| Research and development | 6.28M | 6.63M | 5.72M | 7.74M | 6.15M | 3.40M | 3.05M | 2.52M | 1.10M | -901.0K |
| Selling, general and administrative | 8.46M | 5.00M | 4.13M | 5.58M | 5.20M | 5.69M | 4.19M | 4.71M | 4.14M | 8.73M |
| Operating income | -14.7M | -11.6M | -9.86M | -13.3M | -11.4M | -9.09M | -7.24M | -7.24M | 5.27M | -9.63M |
| Depreciation and amortization | 47.0K | 91.0K | 106.0K | 102.0K | 76.0K | 68.0K | 84.0K | 54.0K | 21.0K | 10.0K |
| EBITDA | -14.7M | -11.5M | -9.75M | -13.2M | -11.3M | -9.02M | -7.16M | -7.19M | 5.29M | -9.63M |
| Interest expense | 131.3M | 44.0K | 80.0K | 103.0K | 0 | 237.0K | 333.0K | |||
| Income before tax | -13.1M | -11.4M | -10.7M | -13.2M | -11.3M | -9.17M | -7.25M | -7.26M | -7.59M | -9.66M |
| Income tax | 182.0K | -118.0M | -44.0K | 0 | 0 | 20.0K | 2.32M | 28.0K | ||
| Net income | -13.1M | -11.4M | -10.7M | -13.2M | -11.3M | -9.17M | -7.25M | -7.26M | -7.59M | -9.66M |
| Earnings per share, basic | -0.29 | -0.73 | -1.05 | -1.81 | -1.59 | -1.29 | -1.70 | -2.41 | -2.76 | 0.40 |
| Earnings per share, diluted | -0.29 | -0.73 | -1.05 | -1.81 | -1.59 | -1.29 | -1.70 | -2.41 | -2.76 | 0.40 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.91M | 3.11M | 2.47M | 2.44M | 13.5M | 19.6M | 28.8M | 5.24M | 10.8M | 2.71M |
| Short-term investments | 74.7M | 2.36M | 3.92M | 5.76M | 2.00M | 5.00M | 2.52M | 27.0K | 505.0K | |
| Receivables | 241.0K | 300.0K | 1.49M | 103.0K | 174.0K | 340.0K | 101.0K | 65.0K | 35.0K | 15.0K |
| Inventory | 584.0K | 0 | -42.0K | -103.0K | -174.0K | -5.00K | -2.62M | 73.0K | 0 | |
| Current assets | 79.8M | 5.82M | 7.92M | 8.81M | 15.9M | 25.3M | 35.9M | 5.83M | 10.9M | 3.31M |
| Property, plant and equipment | 93.0K | 80.0K | 146.0K | 221.0K | 244.0K | 251.0K | 228.0K | 259.0K | 90.0K | 53.0K |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 81.5M | 6.03M | 8.33M | 9.54M | 16.8M | 26.3M | 37.1M | 6.09M | 11.0M | 3.37M |
| Accounts payable | 511.0K | 165.0K | 357.0K | 116.0K | 279.0K | 275.0K | 284.0K | 630.0K | 78.0K | 512.0K |
| Current liabilities | 3.42M | 2.46M | 3.79M | 2.07M | 1.98M | 1.34M | 4.83M | 4.76M | 528.0K | 783.0K |
| Long-term debt | 0 | 76.0K | ||||||||
| Total debt | 865.0K | 111.0K | 231.0K | 462.0K | 680.0K | 813.0K | 903.0K | 76.0K | ||
| Total liabilities | 3.99M | 2.50M | 3.83M | 2.25M | 2.39M | 1.97M | 5.59M | 4.76M | 556.0K | 1.17M |
| Shareholders' equity | 77.6M | 3.53M | 4.50M | 7.29M | 14.4M | 24.3M | 31.5M | 1.33M | 9.99M | 1.70M |
| Shares outstanding | 67.2M | 19.4M | 11.7M | 7.89M | 7.11M | 7.11M | 7.19M | 3.01M | 2.01M | 15.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -13.0M | -8.83M | -8.53M | -11.5M | -9.35M | -7.25M | -6.45M | -5.31M | -4.86M | -786.0K |
| Capital spending | -60.0K | -25.0K | -33.0K | -84.0K | -69.0K | -91.0K | -216.0K | -223.0K | -58.0K | -25.0K |
| Free cash flow | -13.1M | -8.85M | -8.57M | -11.6M | -9.42M | -7.34M | -6.67M | -5.53M | -4.91M | -811.0K |
| Cash from investing | -72.4M | 1.54M | 1.97M | -3.84M | 3.20M | -2.77M | -2.45M | -223.0K | -58.0K | -25.0K |
| Cash from financing | 86.2M | 7.94M | 6.56M | 4.32M | 4.32M | -3.38M | 36.8M | -18.0K | 13.0M | 3.08M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | -3.38K | 36.8M | 12.7M | 409.0K | ||||||
| Change in cash | 810.0K | 646.0K | -2.00K | -11.1M | -6.15M | -13.4M | 27.9M | -5.55M | 8.11M | 2.27M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Nov 3, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Nov 3, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 3, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 27, 2026 | Current report | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
| 8-K · Current report | Oct 20, 2026 | Current report | SEC |
| 8-K · Current report | Oct 6, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 28, 2026 | Current report | SEC |
| 8-K · Current report | Aug 11, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 21, 2026 | Current report | SEC |
| 8-K · Current report | Jul 7, 2026 | Current report | SEC |
| 8-K · Current report | Jun 30, 2026 | Current report | SEC |
| 8-K · Current report | Jun 25, 2026 | Current report | SEC |
| 8-K · Current report | Jun 23, 2026 | Current report | SEC |
| 8-K · Current report | Jun 16, 2026 | Current report | SEC |
| 8-K · Current report | Jun 9, 2026 | Current report | SEC |
| 8-K · Current report | Jun 2, 2026 | Current report | SEC |
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 8-K · Current report | May 15, 2026 | Current report | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Current report | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| 8-K · Current report | Apr 22, 2026 | Current report | SEC |
| 8-K · Current report | Apr 14, 2026 | Current report | SEC |
| 8-K · Current report | Apr 13, 2026 | Current report | SEC |
| 424B5 · Prospectus | Apr 10, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 10, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Current report | SEC |
| 8-K · Current report | Mar 24, 2026 | Current report | SEC |
| 8-K · Current report | Mar 17, 2026 | Current report | SEC |
| 8-K · Current report | Mar 10, 2026 | Current report | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| 8-K · Current report | Mar 3, 2026 | Current report | SEC |
| 8-K · Current report | Feb 24, 2026 | Material contract | SEC |
| 8-K · Current report | Feb 24, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 19, 2026 | Current report | SEC |
| 8-K · Current report | Feb 12, 2026 | Current report | SEC |
| 8-K · Current report | Feb 5, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 23, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 8-K · Current report | Nov 26, 2025 | Current report | SEC |
| 424B3 · Prospectus | Nov 19, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 19, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 5, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 31, 2025 | Big-stake notice | SEC |
| S-3/A · Registration statement, amended | Oct 28, 2025 | Offer document | SEC |
| S-3/A · Registration statement, amended | Oct 28, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 16, 2025 | Current report | SEC |
| 8-K · Current report | Oct 14, 2025 | Current report | SEC |
| S-3 · Registration statement | Oct 14, 2025 | Offer document | SEC |
| S-3 · Registration statement | Oct 14, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 7, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 3, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 1, 2025 | Current report | SEC |
| D | Sep 29, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 23, 2025 | Current report | SEC |
| 8-K · Current report | Sep 19, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 16, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 9, 2025 | Current report | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| 8-K · Current report | Aug 27, 2025 | Financing | SEC |
| 8-K · Current report | Aug 25, 2025 | Financing | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Financing | SEC |
| 8-K · Current report | Jul 30, 2025 | Financing | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jul 22, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 22, 2025 | Current report | SEC |
| 8-K · Current report | Jul 17, 2025 | Financing | SEC |
| 8-K · Current report | Jul 8, 2025 | Current report | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| 8-K · Current report | Jun 17, 2025 | Financing | SEC |
| 8-K · Current report | Jun 11, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 9, 2025 | Current report | SEC |
| 8-K · Current report | Jun 5, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 30, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 23, 2025 | Financing | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 17, 2025 | Current report | SEC |
| 8-K · Current report | Apr 15, 2025 | Current report | SEC |
| 8-K · Current report | Apr 9, 2025 | Current report | SEC |
| 424B3 · Prospectus | Apr 8, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Apr 8, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Apr 8, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Apr 8, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Apr 3, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 2, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 1, 2025 | Current report | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 28, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 28, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 27, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 27, 2025 | Offer document | SEC |
| S-3/A · Registration statement, amended | Mar 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2025 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Mar 17, 2025 | Other filings | SEC |
| S-3 · Registration statement | Mar 10, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Feb 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Feb 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 25, 2025 | Current report | SEC |
| 424B3 · Prospectus | Feb 21, 2025 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Feb 18, 2025 | Meeting notice | SEC |
| D | Feb 18, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 14, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Feb 12, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 12, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 11, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Feb 11, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 11, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Feb 11, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Feb 10, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 10, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 10, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 10, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 10, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 10, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Feb 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 7, 2025 | Material contract | SEC |
| S-1 · Registration statement | Feb 4, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 4, 2025 | Current report | SEC |
| 424B3 · Prospectus | Feb 3, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 3, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 27, 2025 | Current report | SEC |
| 8-K · Current report | Jan 24, 2025 | Management or board change | SEC |
| D | Jan 22, 2025 | Other filings | SEC |
| D | Jan 22, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 21, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Jan 16, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 10, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 7, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jan 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 6, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jan 6, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 6, 2025 | Current report | SEC |
| 8-K · Current report | Dec 30, 2024 | Current report | SEC |
| 8-K · Current report | Dec 19, 2024 | Management or board change | SEC |
| 424B3 · Prospectus | Dec 10, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 10, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 10, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Nov 6, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Nov 6, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 6, 2024 | Meeting notice | SEC |
| 8-K · Current report | Oct 31, 2024 | Current report | SEC |
| 424B3 · Prospectus | Oct 15, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Oct 15, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 15, 2024 | Current report | SEC |
| 8-K · Current report | Oct 11, 2024 | Current report | SEC |
| 424B3 · Prospectus | Oct 1, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Oct 1, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 30, 2024 | Current report | SEC |
| 8-K · Current report | Sep 17, 2024 | Current report | SEC |
| 8-K · Current report | Sep 11, 2024 | Current report | SEC |
| 424B3 · Prospectus | Aug 22, 2024 | Offer document | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Microbot Medical Inc.’s releases · as of Nov 12, 2026
- Common shares
- 67,164,801
- Fully diluted
- 67,164,801
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 67,164,801 | Nov 12, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$4.50 · expire about Oct 2027 |
| Warrants · US$2.13 · expire about Feb 2027 |
| Warrants · US$2.10 · expire about Jan 2027 |
| Warrants · US$1.75 · expire about Jan 2027 |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 67,164,801 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gregory T Schiffman Other companies: Fabric.AI, Inc. (Director · Since at least Jan 30, 2018); Nanomix Corporation (Director · Mar 2, 2022 – Dec 21, 2022 · Past); Absci Corporation (Chief Financial Officer · Jul 21, 2021 – Mar 1, 2023 · Past); Iovance Biotherapeutics, Inc. (Chief Financial Officer · Oct 3, 2016 – Nov 14, 2016 · Past); Dendreon Corp (EVP · Dec 18, 2006 – Oct 20, 2013 · Past); Xenogen Corp (Director · Aug 9, 2006 – Aug 9, 2006 · Past); Vnus Medical Technologies Inc (Director · Apr 3, 2006 – Jun 17, 2009 · Past); Affymetrix Inc (EVP & Chief Financial Officer · Jan 5, 2006 – Aug 4, 2006 · Past) | Chief Financial Officer · Jan 1, 2014 – Mar 15, 2016 · Past |
| R. Scott Greer Other companies: Nektar Therapeutics (Managing Director, Numenor Ventures, LLC · Since at least Sep 15, 2015); Inogen, Inc (Director · Aug 3, 2015 – May 10, 2021 · Past); Aravive Inc (Director · Jun 29, 2015 – Dec 20, 2017 · Past); Sientra Inc (Director · Jun 26, 2015 – Jun 5, 2018 · Past) | Director · Jan 1, 2016 – Jan 1, 2016 · Past |
| Scott Burell Other companies: Expion360 Inc. (Chairman of the Board and Independent Director · Since at least Oct 16, 2025); DIH Holdings US, Inc (Director · Since at least Aug 4, 2025); AgEagle Aerial Systems, Inc. (Director · Mar 26, 2018 – May 21, 2019 · Past); CombiMatrix Corp (CFO, Secretary & Treasurer · Apr 7, 2011 – Nov 14, 2017 · Past) | Director · Since at least Nov 28, 2016 |
| Ricardo B Levy Other companies: Renegy Holdings Inc (Director · Oct 1, 2007 – Apr 17, 2009 · Past); Accelrys Inc (Director · Aug 4, 2006 – Mar 6, 2013 · Past) | Director · Sep 26, 2006 – Jan 1, 2016 · Past |
| Desmond H Oconnell Jr Other companies: Serologicals Corp (Director · Jan 12, 2006 – Jul 14, 2006 · Past) | Director · Jan 10, 2007 – Mar 7, 2007 · Past |
| Harel Gadot Other companies: Brenmiller Energy Ltd (Director · Since at least Mar 18, 2026) | CEO, President and Chairman · Since at least Dec 23, 2019 |
| Irving Weissman Other companies: Forty Seven Inc (Director · Jun 27, 2018 – Apr 7, 2020 · Past) | Director · Oct 1, 2006 – Apr 1, 2016 · Past |
| Martin J. Madden Other companies: NovoCure Limited (Director · Since at least May 21, 2019) | Director · Since at least Oct 23, 2019 |
| Yoseph Bornstein Other companies: Can-Fite BioPharma Ltd. (Director · Since at least Mar 18, 2026) | Director · Nov 28, 2016 – Nov 2, 2023 · Past |
| Aileen Stockburger | Director · Since at least Apr 1, 2020 |
All 33 people
| Person | Seat |
|---|---|
| Alan O Trounson | Director · Jul 7, 2014 – Jan 1, 2016 · Past |
| Allison Rosefort | VP, Marketing · Since at least Apr 23, 2025 |
| Alon Tamir | VP, Sales, EMEA · Since at least May 5, 2026 |
| Ann Tsukamoto | EVP, Research and Development · Mar 10, 2009 – Jan 27, 2015 · Past |
| Christina Bailey | VP, Sales · Since at least Jun 16, 2026 |
| David Ben Naim | Chief Financial Officer · Nov 28, 2016 – Dec 28, 2017 · Past |
| David Wilson | Director · Since at least Dec 17, 2024 |
| Earl Adamy | VP, Strategic Marketing & Business Development · Since at least Mar 10, 2026 |
| Eran Cohen | VP, Global Integration · Since at least Nov 4, 2026 |
| Eyal Morag | Chief Medical Officer · May 1, 2020 – Aug 1, 2023 · Past |
| John J Schwartz | Director · Apr 18, 2006 – Jan 1, 2016 · Past |
| Juan Diaz-Cartelle | Chief Medical Officer · Since at least Dec 1, 2023 |
| Kenneth Blair Stratton | General Counsel · May 15, 2013 – Jun 17, 2016 · Past |
| Martin M McGlynn | President & CEO, Director · Mar 31, 2006 – Jan 8, 2016 · Past |
| Mayer Solomon | Director · Nov 28, 2016 – Nov 28, 2016 · Past |
| Moshe Shoham | Director · Nov 28, 2016 – Oct 5, 2017 · Past |
| Naama Moav | VP, Human Resources · Since at least Apr 23, 2025 |
| Noa Ofer | VP, Quality Assurance and Regulatory Affairs · Since at least Nov 4, 2026 |
| Prattipati Laxminarain | Director · Since at least Dec 6, 2017 |
| Rachel Vaknin | Chief Financial Officer · Since at least Apr 1, 2022 |
| Simon Sharon | General Manager, CTO · Since at least Apr 7, 2021 |
| Tal Wenderow | Director · Since at least Aug 1, 2020 |
| Yehezkel Himelfarb | COO and General Manager, Director · Dec 5, 2016 – Oct 15, 2017 · Past |
Log in to ask 6ix AI your own questions about Microbot Medical Inc.